Table 1.
Characteristics of Patients Included in the Study
| Patient no. | Age, years | Sex | Diagnosis | Stage ISCL/EORTC 2007 | T-cell receptor clonality | Ki67+ cells, % | Density grade of tumor cells |
|---|---|---|---|---|---|---|---|
| 1 | 67 | M | PEP | Monoclonal with polyclonal background | 1–2 | ||
| 2 | 67 | M | PEP | Polyclonal | 1 | ||
| 3 | 67 | M | PEP | Polyclonal | 2 | ||
| 4 | 73 | M | PEP | Polyclonal | 1 | ||
| 5 | 55 | F | MF patch/plaque | T2N0B0M0 stage IB | Monoclonal with polyclonal background | <5 | 2 |
| 6 | 68 | M | MF patch/plaque | T2N0B0M0 stage IB | Monoclonal | 30 | 2 |
| 7 | 77 | M | MF patch/plaque | T2N0B0M0 stage IB | Monoclonal | 45 | 3 |
| 8 | 62 | F | MF patch/plaque | T2N0B0M0 stage IA | Oligoclonal | 5 | 2 |
| 9 | 73 | M | MF patch/plaque | T2N0B0M0 stage IB | Monoclonal | 40 | 3–4 |
| 10 | 78 | F | MF tumor | T3N0B0M0 stage IIB | Monoclonal | 50 | 4 |
| 11 | 87 | F | MF tumor | T3NxB0M0 stage IIB | Monoclonal | 50 | 4 |
| 12 | 61 | F | MF tumor | T3NxB0M0 stage IIB | Monoclonal with polyclonal background | 50 | 4 |
| 13 | 72 | M | MF tumor | T3N0B0M0 stage IIB | Monoclonal | 40 | 4 |
| 14 | 75 | M | MF tumor | T3N0B0M0 stage IIB | Monoclonal | 40 | 3 |
ISCL/EORTC, International Society of Cutaneous Lymphoma and the European Organization of Research and Treatment of Cancer; F, female; M, male.